Drug intelligence / Profile preview

iberdomide + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

This combination is an investigational multi-agent chemotherapy and immunotherapy regimen for relapsed or refractory aggressive B-cell lymphoma. - **Iberdomide** is a cereblon E3 ligase modulator (CELMoD) that induces degradation of transcription factors Ikaros and Aiolos, enhancing immune response and inhibiting tumor growth. - **Polatuzumab vedotin** is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD79b linked to the cytotoxic agent monomethyl auristatin E, delivering the toxin selectively to B cells. - **Rituximab** is an anti-CD20 monoclonal antibody that mediates B-cell lysis via immune and direct cytotoxic mechanisms. - **Cyclophosphamide** is an alkylating agent cross-linking DNA and inhibiting cell division. - **Doxorubicin** is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, blocking cell replication. - **Prednisone** is a corticosteroid that reduces inflammation and has lympholytic (anti-lymphocyte) effects. This regimen is studied for patients with relapsed or refractory aggressive B-cell lymphoma in clinical trials[5].

Other names: CC-220 + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone

Targets

CD20 (B-lymphocyte antigen CD20)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)B-cell antigen receptor complex-associated protein beta chainIKZF1 (Ikaros family zinc finger protein 1)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on iberdomide + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iberdomide + polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.

Explore the full profile